Ehave Archives - Green Market Report

Debra BorchardtFebruary 15, 2022
Ehave-Inc.-EHVVF-offers-Ketamine-delivered-to-your-home.png

4min00

Ehave, Inc. (OTC Pink: EHVVF) reported that its wholly-owned subsidiary, KetaDASH has started clinical operations that are offering in-home ketamine therapy to patients suffering from treatment-resistant mental health issues. Ehave said that the treatment will be offered in the San Francisco Bay Area and Greater Sacramento Area first with plans to expand to other markets in the coming months.

“I have over-seen over 600 successful ketamine treatments and have been amazed by the positive results,” said Jeffrey D. Kamlet, MD, Chief Medical Officer of Ehave. “We are pleased to begin our U.S. rollout in Sacramento and San Francisco, with plans to scale our business in other cities over the coming months. Even though ketamine is a relatively safe drug to administer, we have made patient safety our top priority. As such, KetaDASH treatments begin with a telehealth med screen and then treatments will be conducted by a team of experienced nurses who will come to your home, office, or mobile location and administer your session. Post ketamine therapy will be available and is recommended. We believe this will give our clients the confidence in knowing they are receiving the utmost support throughout their treatment experience. This pioneering approach is a departure from ketamine telehealth models, which mail prescriptions and do not provide in-person support or guidance during the psychedelic experience.”

The service isn’t cheap. A two-hour ketamine treatment with psychotherapy costs $899. A one-hour ketamine treatment is $599 and that comes with an experienced nurse.  KetaDASH treatments will be conducted by a team of experienced nurses that can go to a patient’s home, office, or mobile location after initial telemedicine screening and provide a complete ketamine experience, with a focus on set and setting, with packages that include telemedicine integration with psychotherapists.

This approach is different from other companies that mostly offer in-clinic intravenous, treatment, or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision. A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the patient’s home. KetaDASH also offers other IV therapies for hydration and wellness.

Ben Kaplan, CEO of Ehave, said, “For patients with mental health disorders, the need for more effective treatment options is greater now than it ever has been in the past. When used at sub-anesthetic doses, ketamine has proven effective in treating many psychiatric disorders. KetaDASH will provide better access to this treatment for a larger patient population in a safe and convenient way. Through our KetaDASH mobile clinics, patients will benefit from receiving the ketamine therapy in the privacy and comfort of their own homes. Patient safety is our top priority, so all ketamine treatments will be delivered by certified medical professionals. The KetaDASH platform will utilize proprietary software developed by Ehave which will allow patients and their associated nurses to view detailed reports on the ketamine therapy’s progress.”

 


StaffJanuary 27, 2021
Psychedelica.jpg

4min00

Mydecine

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF)  has submitted a formal application to list its common shares on the NASDAQ Stock Exchange. NASDAQ is the second-largest exchange by market capitalization worldwide and is home to many of the world’s best technology companies. “We believe the Company is entering an accelerated growth phase and the timing could not be better for listing our Shares to NASDAQ,” said Josh Bartch, CEO & Chair of Mydecine. “This listing is intended to open the investment opportunity to a larger and more diverse pool of investors and help create greater shareholder value. A listing on the NASDAQ Capital Market is a natural progression for the Company and our shareholders.”

NeonMind

NeonMind Biosciences Inc. (CSE: NEON) has appointed pharmaceutical executive Robert Tessarolo as its President and Chief Executive Officer.
Mr. Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently he held the position of President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., a psychedelic drug discovery and drug development company now traded on the NEO exchange, from September 2019 to January 2020.  Prior, Mr. Tessarolo was President and Chief Executive Officer of Cipher Pharmaceuticals Inc., a diversified specialty pharmaceutical company listed on the Toronto Stock Exchange. His experience includes executive and key leadership roles that span over two decades including  commercial and business development experience with obesity, addiction and neurologic assets.
“These are exciting times in psychedelic drug development. There is an array of dynamic molecules that have been well characterized over the years but have not been adequately studied in the rigorous clinical trials necessary for regulatory approval. NeonMind grabbed my attention with its distinctive focus on the obesity market and desire to bring new treatment modalities to patients suffering with obesity. Over the years promising new drugs to treat obesity have failed to gain regulatory approval.  This market remains underserved and patients dissatisfied with current treatment options. A safe and effective new approach would be well received,” says NeonMind President and CEO, Robert Tessarolo. “NeonMind’s unique intellectual property portfolio makes it well positioned for growth. I’m grateful to be at the helm of this organization to lead its growth as it matures and makes what could be a truly significant impact on the health and well-being of populations worldwide.”
Ehave
Ehave, Inc. (OTC Pink: EHVVF) announced it is exploring how palliative patients could benefit from its Ketamine home delivery platform, KetaDASH. KetaDASH will be based on a dashboard that provides ketamine to patients who have had it prescribed by a physician. The dashboard will provide an objective view of performance metrics and allow KetaDASH to ensure necessary medical guidance, supervision, and support.
Ben Kaplan, CEO of Ehave said, “Our goal is to provide an IV service that will allow medical professionals to provide psychedelic-assisted therapies in the comfort and convenience of their patients’ homes. We believe a large number of patients prefer a medical technician come to their home over going to a clinic.”

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.